Cybin has announced the graduation of highly-skilled facilitators from its EMBARK Psychedelic-Assisted Psychotherapy Training Program.
Awakn’s wholly-owned subsidiary, Awakn Oslo AS, has entered into a debt financing agreement with TD Veen AS, a family-owned, Norwegian investment company and current shareholder of...
Beckley Psytech has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited, in an all-equity transaction.
HMNC Brain Health has raised €14.3m in a funding series, raised from existing investors, including Carsten Maschmeyer, the Jahr Group and Guntard Gutmann.
Small Pharma has had its second United States patent granted by the United States Patent Office.
Silo Wellness has confirmed it has acquired Dyscovry Science – a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives, targeting irritable bowel...
A wholly-owned subsidiary of HYTN Innovations Inc.,
The European Psychiatric Association (EPA) is joining the Psychedelic Access and Research European Alliance (PAREA) as a full member.
Palo Santo has announced the closing of its USD$50m (~£134.10m) fund which will go towards a diverse portfolio of businesses developing innovative psychedelic medicines and therapies.
Biomind Labs has confirmed that it has had a Pre-Investigational New Drug (Pre-IND) meeting granted by the U.S.
